Companies in #Alpha-1 Antitrypsin Deficiency (AATD)
Found 1 company operating in this sector.
Wave Life Sciences is a clinical-stage RNA medicines company using its proprietary PRISM platform to design stereopure oligonucleotides that target genetic diseases, metabolic disorders, and neurological conditions. Lead programs include WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD), WVE-003 for Huntington's disease, WVE-007 for obesity, and WVE-N531 for Duchenne muscular dystrophy, with a strategic collaboration with GSK to accelerate development of RNA-based therapeutics.